NEA powers next-generation cell and gene therapy startup Senti to $53MA round – FierceBiotech
FierceBiotech |
NEA powers next-generation cell and gene therapy startup Senti to $53MA round
FierceBiotech New Enterprise Associates (NEA) has led a $53 million bet on the future of cell and gene therapies. The series A round sets JLABS resident Senti Biosciences up to use advances in synthetic biology to create more targeted, controllable therapies than … Senti Biosciences Secures $53 Million Series A to Build the Future of Gene and Cell-Based Therapies All-star team of synthetic biologists raise $53 million for cancer therapy startup Senti |
